Empresas Iansa S.A (IANSA) - Total Liabilities
Based on the latest financial reports, Empresas Iansa S.A (IANSA) has total liabilities worth CL$361.53 Million CLP (≈ $404.32K USD) as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore IANSA cash flow conversion to assess how effectively this company generates cash.
Empresas Iansa S.A - Total Liabilities Trend (2014–2024)
This chart illustrates how Empresas Iansa S.A's total liabilities have evolved over time, based on quarterly financial data. Check Empresas Iansa S.A (IANSA) liquid assets ratio to evaluate the company's liquid asset resilience ratio.
Empresas Iansa S.A Competitors by Total Liabilities
The table below lists competitors of Empresas Iansa S.A ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Immunic Inc
NASDAQ:IMUX
|
USA | $30.73 Million |
|
Shenyang Cuihua Gold and Silver Jewelry Co Ltd
SHE:002731
|
China | CN¥4.31 Billion |
|
Vivozon Healthcare Inc
KQ:082800
|
Korea | ₩92.82 Billion |
|
Eightco Holdings Inc.
NASDAQ:ORBS
|
USA | $16.77 Million |
|
Enea AB
ST:ENEA
|
Sweden | Skr648.30 Million |
|
Onewater Marine
NASDAQ:ONEW
|
USA | $1.16 Billion |
|
Ellsworth Convertible Growth & IF
NYSE MKT:ECF
|
USA | $1.19 Million |
|
Harvatek Corp
TW:6168
|
Taiwan | NT$653.70 Million |
Liability Composition Analysis (2014–2024)
This chart breaks down Empresas Iansa S.A's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see IANSA market cap overview.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.54 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 1.13 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.53 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Empresas Iansa S.A's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Empresas Iansa S.A (2014–2024)
The table below shows the annual total liabilities of Empresas Iansa S.A from 2014 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | CL$340.76 Million ≈ $381.09K |
-0.34% |
| 2023-12-31 | CL$341.94 Million ≈ $382.41K |
-9.00% |
| 2022-12-31 | CL$375.74 Million ≈ $420.21K |
+33.56% |
| 2021-12-31 | CL$281.33 Million ≈ $314.63K |
-5.52% |
| 2020-12-31 | CL$297.78 Million ≈ $333.02K |
+11.89% |
| 2019-12-31 | CL$266.13 Million ≈ $297.62K |
+6.10% |
| 2018-12-31 | CL$250.82 Million ≈ $280.50K |
-9.59% |
| 2017-12-31 | CL$277.43 Million ≈ $310.26K |
+18.71% |
| 2016-12-31 | CL$233.71 Million ≈ $261.37K |
-14.16% |
| 2015-12-31 | CL$272.25 Million ≈ $304.47K |
+4.66% |
| 2014-12-31 | CL$260.12 Million ≈ $290.90K |
-- |
About Empresas Iansa S.A
Empresas Iansa S.A. manufactures and markets various food products in Chile and internationally. It offers sugar, sweeteners, delicacies, expanded cereals, premium juices and pet foods under Iansa sugar, Iansa Zero K, Iansa Agro, Tanmaya, Fellness, Cannes, and Biomaster brand name; sugar, petfood cossette, molasses, concentrated juices, fruit and vegetable pulps, tomato paste, and food ingredient… Read more